| 摘要 |
Compounds of general formula I or a pharmaceutically acceptable salts, derivatives or prodrugs thereof are of use in treatment of cancer; wherein R<SUP>1 </SUP>and R<SUP>2 </SUP>are independently selected from the group consisting of hydrogen, substituted or unsubstituted C<SUB>1</SUB>-C<SUB>12 </SUB>alkyl, substituted or unsubstituted C<SUB>2</SUB>-C<SUB>12 </SUB>alkenyl, substituted or unsubstituted C<SUB>2</SUB>-C<SUB>12 </SUB>alkynyl, C<SUB>2</SUB>-C<SUB>12 </SUB>alkenylidene, substituted or unsubstituted C<SUB>3</SUB>-C<SUB>12 </SUB>alkynylidene and substituted or unsubstituted C<SUB>2</SUB>-C<SUB>12 </SUB>acyl.
|
